-
Akeso Biopharma and Shanghai Pharmaceuticals Collaborate on Liposarcoma Treatment
•
China-based Akeso Biopharma (HKG: 9926) has announced a strategic collaboration agreement with compatriot firm Shanghai Pharmaceuticals Holding Co., Ltd (SHA: 601607). The partnership aims to accelerate the development of Akeso’s cadonilimab (AK104) in combination with Shanghai Pharmaceuticals’ SPH4336 for the treatment of well-differentiated liposarcoma (WDLS) and dedifferentiated liposarcoma (DDLS). About…
-
F-star Therapeutics’ Acquisition by invoX Pharma Cleared by CFIUS
•
UK biotech F-star Therapeutics, Inc. (NASDAQ: FSTX) has announced that it has received clearance from the Committee on Foreign Investment in the United States (CFIUS) for the all-cash acquisition by invoX Pharma Limited, a UK-based subsidiary of China’s Sino Biopharmaceutical Ltd (HKG: 1177). This clearance is a significant step towards…
-
Biocytogen’s YH008 Gets NMPA Approval for Phase I Study
•
China-based Biocytogen Pharmaceuticals (Beijing) Co., Ltd has announced receiving approval from the China National Medical Products Administration (NMPA) to conduct an open-label Phase I dosage escalation study. The study will assess the safety, tolerability, and preliminary anti-tumor activity of YH008, an internally developed first-in-class PD-1 x CD40 bispecific antibody (BsAb)…
-
Heranova Closes $10M Seed Round for Women’s Health Solutions
•
Heranova Lifesciences Holding, a provider of women’s health solutions, has announced the successful closure of a seed financing round at USD 10 million. The round was co-led by Pivotal Bioventure Partners and Sinovation Ventures, with the proceeds earmarked for commercialization efforts in the Asia-Pacific region. This includes the market launch…
-
Inmagene’s Tavalisse First Prescribed in China for ITP Treatment
•
China-based Inmagene Biopharmaceuticals has announced that its in-licensed drug Tavalisse (fostamatinib) has been first prescribed at the Hainan branch of Shanghai’s Ruijin Hospital. This marks a significant milestone in the availability of the oral spleen tyrosine kinase (SYK) inhibitor for the treatment of immunization thrombocytopenia (ITP) in China. Background and…
-
China’s Party and State Institutions Reshuffle: Key Changes for Healthcare and Finance
•
The second plenary session of the 20th Communist Party of China (CPC) Central Committee has passed a significant plan to reshuffle party and national institutions. Several changes will impact the healthcare industry and other key sectors, reflecting a strategic reorganization aimed at enhancing governance and efficiency. Healthcare Sector Changes Financial…
-
BrightGene’s Generic Halaven Approved for Marketing in China
•
China-based BrightGene Bio-Medical Technology Co., Ltd (SHA: 688166) has received marketing approval from the National Medical Products Administration (NMPA) for its generic version of Japan-based Eisai’s (TYO: 4523) cancer therapy Halaven (eribulin). The approval signifies that BrightGene’s product, trade-named BoLiNing, has passed the generic quality consistency evaluation (GQCE). BoLiNing is…
-
Abcam and MEDx Expand Strategic Partnership on Claudin 18.2 Diagnosis
•
UK-based abcam (NASDAQ:ABCM) has announced a licensing agreement with China-headquartered MEDx Translational Medicine Co., Ltd, further expanding their strategic partnership initiated in 2021. The collaboration will focus on development, regulatory filings, and commercialization related to Claudin 18.2 concomitant diagnosis. Financial details of the agreement were not disclosed. About AbcamAbcam is…
-
Inovio and ApolloBio Announce Positive Phase III Data for VGX-3100 Vaccine
•
US-based Inovio Pharmaceuticals (NASDAQ: INO) and China-based ApolloBio Corp. (NEEQ:430187) have announced positive data from the Phase III Reveal 2 study for the DNA therapeutic vaccine VGX-3100 (known as ABC-3100 in China). The two firms are co-developing VGX-3100 under a 2018 licensing deal, with ApolloBio holding development and commercialization rights…
-
Sunshine Medical Procurement Platform Announces VBP Tender Results for Yangtze River Delta
•
Shanghai’s Sunshine Medical Procurement All-In-One (SMPA) platform has revealed the resultant winning bids and spare supply manufacturers for the Yangtze River Delta Alliance volume-based procurement (VBP) tender. The tender involves Shanghai, Zhejiang, and Anhui, and the platform has also disclosed the prices of the winning bids and spare products. Tender…
-
Neo Modulus Secures Series B Funding for Regenerative Medical Device Development
•
Neo Modulus, a developer of regenerative implantable medical devices based in Suzhou, has reportedly raised “hundreds of millions” of renminbi in a Series B financing round. The round was led by SND Financial Holdings, with participation from JM Capital, CDH Investments, Hui Ding Capital, 10Fund, and Boya Clivia Venture Capital.…
-
Takeda’s Exkivity Receives First Prescription in China with Innovative Payment Solutions
•
Takeda Pharmaceutical Co., Ltd has announced the first prescription of its lung cancer therapy Exkivity (mobocertinib) in China. The Japanese pharmaceutical giant will partner with China-based health platform MediTrust Health to launch innovative payment solutions for the drug in China, making this advanced therapy more accessible to patients. Clinical Need…
-
Pudong New Area Grants Duty-Free Import Qualifications to Seven Companies
•
Seven companies have been awarded scientific and technological innovation duty-free import qualification designations by the foreign R&D center in Pudong New Area. Among the awardees are Fosun Kite Biotechnology Co., Ltd, a joint venture (JV) between Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196) and Gilead subsidiary Kite Pharma, as…
-
Harbour BioMed’s Batoclimab Shows Positive Results in gMG Phase III Trial
•
Harbour BioMed (HKG: 2142), a biotech company operating out of the United States, the Netherlands, and Suzhou (China), has announced positive topline results from its phase III clinical trial of batoclimab (HBM9161) for the treatment of generalized myasthenia gravis (gMG). The pivotal clinical study, designed to confirm the efficacy and…
-
BGI Group Subsidiaries Added to US Trade Blacklist by Commerce Department
•
The US Department of Commerce (DOC)’s Bureau of Industry and Security (BIS) has added 37 companies from various countries and industries to its trade blacklist, including 28 Chinese entities. Among the China-based companies are three subsidiaries of genomics giant BGI Group: BGI Research, BGI Tech Solutions (Hongkong) Co., Ltd, and…
-
Sanyou Biopharmaceuticals Expands Global Reach with New Cambridge Office
•
Sanyou Biopharmaceuticals, a leading provider of biotech CRDMO services, is set to open a new office in the Cambridge Innovation Centre (CIC) on March 2, 2023. This strategic move marks a significant step forward in expanding the company’s global footprint and enhancing its capabilities to serve and collaborate with biotechs…
-
Sanofi’s Dupixent Receives Priority Review for Prurigo Nodosa Treatment
•
French pharmaceutical major Sanofi (NASDAQ: SNY) has announced that it has received priority review status from the Center for Drug Evaluation (CDE) for its Dupixent (dupilumab) to treat prurigo nodosa (PN) in adults. This marks another significant breakthrough in the type 2 inflammation field, following the drug’s indication approval for…
-
China’s Premier Li Keqiang Highlights Economic and Social Advances in Annual Report
•
Premier Li Keqiang delivered his annual Government Work Report at the “Two Sessions” meeting, which includes the National People’s Congress and commenced this week in Beijing. The report highlighted significant economic and social advancements, reflecting the government’s efforts in various sectors. Economic HighlightsDuring 2022, China’s national GDP reached RMB 121…
-
Eli Lilly’s Retevmo Launched in China by Innovent Biologics
•
Eli Lilly & Co’s (NYSE: LLY) Retevmo (selpercatinib) has been officially launched in the Chinese market. The drug is being commercialized by domestic firm Innovent Biologics Inc. (HKEX: 01801) under a partnership deal signed between the two companies in March last year. This collaboration aims to bring innovative treatments to…
